Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal

Biomedicine and Pharmacotherapy

Volumn 65, Issue 4, 2011, Pages 286-292

  Chuang, Hui Yen ^a   Chang, Ya Fang ^a   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Fatty acid synthase; Human colorectal carcinoma; Orlistat

Indexed keywords

ACETIC ACID; ANTINEOPLASTIC AGENT; CARBON 11; CASPASE 3; FATTY ACID SYNTHASE; FIALURIDINE; IODINE 131; LUCIFERASE; TETRAHYDROLIPSTATIN; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HT29; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; FATTY ACID SYNTHESIS; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METABOLIC INHIBITION; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FATTY ACID SYNTHETASE COMPLEX; FLOW CYTOMETRY; GENES, REPORTER; HERPESVIRUS 1, HUMAN; HUMANS; LACTONES; LUMINESCENT MEASUREMENTS; MICE; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960389339     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.02.016     Document Type: Article

References (37)

1. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777.
2. Kuhajda F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16:202-208.
3. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980.
4. Pflug B.R., Pecher S.M., Brink A.W., Nelson J.B., Foster B.A. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 2003, 57:245-254.
5. Hochachka P.W., Rupert J.L., Goldenberg L., Gleave M., Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 2002, 24:749-757.
6. Alo P.L., Visca P., Marci A., Mangoni M.A., Botti C., Tondo U.D. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996, 77:474-482.
7. Epstein J.I., Carmichael M., Partin A.W. OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 1995, 45:81-86.
8. Jensen V., Ladekarl M., Holm-Nielsen P., Melsen F., Srensen F.B. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-I in node-negative breast cancer. J Pathol 1995, 176:343-352.
9. Gansler T.S., Hardman W., Hunt D.A., Schaffel S., Hennigar R.A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997, 28:686-692.
10. Mobbs C.V., Makimura H. Block the FAS, lose the fat. Nat Med 2002, 8:335-336.
11. Bandyopadhyay S., Zhan R., Wang Y., Pai S.K., Hirota S., Hosobe S., et al. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 2006, 66:5934-5940.
12. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., Townsend C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000, 97:3450-3454.
13. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000, 60:213-218.
14. Zhou W., Simpson P.J., McFadden J.M., Townsend C.A., Medghalchi S.M., Vadlamudi A., et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003, 63:7330-7337.
15. Funabashi H., Kawaguchi A., Tomoda H., Ömura S., Okuda S., Iwasaki S. Binding site of cerulenin in fatty acid synthetase. J Biochem 1989, 105:751-755.
16. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 1994, 91:6379-6383.
17. Pizer E.S., Wood F.D., Heine H.S., Romantsev F.E., Pasternack G.R., Kuhajda F.P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996, 56:1189-1193.
18. Pizer E.S., Jackisch C., Wood F.D., Pasternack G.R., Davidson N.E., Kuhajda F.P. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996, 56:2645-2747.
19. Pizer E.S., Chrest F.J., DiGiuseppe J.A., Han W.F. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 1998, 58:4611-4615.
20. Orita H., Coulter J., Tully E., Kuhajda F.P., Gabrielson E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res 2008, 14:2458-2464.
21. Loftus T.M., Jaworsky D.E., Frehywot G.L., Townsend C.A., Ronnett G.V., Lane M.D., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288:2379-2381.
22. Wortman M.D., Clegg D.J., D'Alessio D., Woods S.C., Seeley R.J. C75 inhibits food intake by increasing CNS glucose metabolism. Nat Med 2003, 9:483-485.
23. Kridel S.J., Axelrod F., Rozenkrantz N., Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004, 64:2070-2075.
24. Martinez-Villaluenga C., Rupasinghe S.G., Schuler M.A., Gonzalez de Mejia E. Peptides from purified soybean beta-conglycinin inhibit fatty acid synthase by interaction with the thioesterase catalytic domain. FEBS J 2010, 277:1481-1493.
25. Carvalho M.A., Zecchin K.G., Seguin F., Bastos D.C., Agostini M., Rangel A.L., et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 2008, 123:2557-2565.
26. Dowling S., Cox J., Cenedella R.J. Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 2009, 44:489-498.
27. Chang Y.F., Yi-Yu Lin Y.Y., Wang H.E., Liu R.S., Pang F., Hwang J.-J. Monitoring of tumor growth and metastasis potential in MDA-MB-435s/tk-luc human breast cancer xenografts. Nucl Instr Methods Phys Res 2007, 571:155-159.
28. Browne C.D., Hindmarsh E.J., Smith J.W. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 2006, 20:2027-2035.
29. Knowles L.M., Yang C., Osterman A., Smith J.W. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 2008, 283:31378-31384.
30. Liu X., Shi Y., Giranda V.L., Luo Y. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther 2006, 5:494-501.
31. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
32. Helms J.B., Zurzolo C. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic 2004, 5:247-254.
33. Nagy P., Vereb G., Sebestyen Z., Horvath G., Lockett S.J., Damjanovich S., et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 2002, 115:4251-4262.
34. Guo D., Prins R.M., Dang J., Kuga D., Iwanami A., Soto H., et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009, 2(101):1-12. [ra82].
35. Menendez J.A., Lupu R., Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005, 18:375-385.
36. Vavere A.L., Kridel S.J., Wheeler F.B., Lewis J.S. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008, 49:327-334.
37. Yun M., Bang S.H., Kim J.W., Park J.Y., Kim K.S., Lee J.D. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med 2009, 50:1222-1228.